Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Krka, d. d. (KRK.WA)
Novo Mesto, SI
Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved in the research, production, promotion, and sale of various pharmaceutical goods. Its market presence spans Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and numerous other international territories. The company's offerings are categorized into prescription medications, over-the-counter products, and veterinary health solutions. Its prescription drug pipeline targets a broad spectrum of medical conditions, including cardiovascular disorders, gastrointestinal issues, central nervous system ailments, pain management, anti-infective treatments, conditions affecting blood and blood-forming organs, urological problems, diabetes, and oncology. The array of non-prescription items includes products for oral and throat care, cough and cold remedies, analgesics, nasal preparations, vitamin and mineral supplements, products designed to enhance cerebral and peripheral circulation, digestive aids, and various general healthcare products. Furthermore, Krka supplies animal health products such as anti-infectives, antiparasitics, and other specialized formulations for both livestock and companion animals. Beyond its pharmaceutical operations, the company also provides health resort and tourist services. Krka, d. d. was established in 1954 and has its corporate headquarters in Novo Mesto, Slovenia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.36% | +4.35% | +7.18% | +5.65% | +26.90% | +28.37% | +38.69% | +116.47% | +129.05% | +316.60% | +4,784.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.9% ★ Q1'26: +8.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+11.7% Q1'26: -19.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+15.0% Q1'26: +12.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+22.4% ★ Q1'26: +26.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+20.8% ★ Q1'26: +27.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.2% Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.03× ★ Q1'26: 0.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.16B
est: 1.21B (-3.4%)
|
1.17B
est: 1.15B (+1.8%)
|
1.27B
est: 1.25B (+1.3%)
|
1.33B
est: 1.34B (-0.9%)
|
1.49B
est: 1.43B (+4.6%)
|
1.53B
est: 1.56B (-1.4%)
|
1.57B
est: 1.57B (-0.5%)
|
1.72B
est: 1.67B (+2.6%)
|
1.81B
est: 1.76B (+2.8%)
|
1.91B
est: 1.90B (+0.5%)
|
2.04B
est: 2.03B (+0.5%)
|
2.11B
2.07B – 2.14B
+4.1% YoY
|
2.22B
2.14B – 2.28B
+5.2% YoY
|
2.32B
2.26B – 2.37B
+4.4% YoY
|
2.46B
2.39B – 2.51B
+5.9% YoY
|
2.80B
2.72B – 2.86B
+13.9% YoY
|
| EBITDA |
286.22M
est: 347.13M (-17.5%)
|
227.45M
est: 332.33M (-31.6%)
|
305.40M
est: 360.16M (-15.2%)
|
341.13M
est: 387.23M (-11.9%)
|
396.09M
est: 411.25M (-3.7%)
|
451.00M
est: 448.43M (+0.6%)
|
471.75M
est: 453.51M (+4.0%)
|
542.02M
est: 482.35M (+12.4%)
|
472.19M
est: 506.07M (-6.7%)
|
512.07M
est: 538.02M (-4.8%)
|
550.75M
est: 575.40M (-4.3%)
|
598.81M
587.51M – 606.57M
+4.1% YoY
|
629.83M
606.45M – 646.85M
+5.2% YoY
|
657.32M
638.77M – 670.58M
+4.4% YoY
|
696.21M
676.56M – 710.25M
+5.9% YoY
|
793.03M
770.64M – 809.02M
+13.9% YoY
|
| EBIT |
181.04M
est: 272.10M (-33.5%)
|
116.93M
est: 260.50M (-55.1%)
|
176.36M
est: 282.31M (-37.5%)
|
203.22M
est: 303.53M (-33.0%)
|
284.85M
est: 322.35M (-11.6%)
|
339.31M
est: 351.50M (-3.5%)
|
362.91M
est: 355.48M (+2.1%)
|
434.33M
est: 378.09M (+14.9%)
|
367.60M
est: 396.68M (-7.3%)
|
419.56M
est: 429.99M (-2.4%)
|
457.20M
est: 459.86M (-0.6%)
|
478.57M
469.53M – 484.77M
+4.1% YoY
|
503.36M
484.67M – 516.96M
+5.2% YoY
|
525.33M
510.50M – 535.93M
+4.4% YoY
|
556.41M
540.70M – 567.63M
+5.9% YoY
|
633.78M
615.89M – 646.57M
+13.9% YoY
|
| Net Income |
158.25M
est: 166.18M (-4.8%)
|
108.45M
est: 107.55M (+0.8%)
|
152.60M
est: 138.89M (+9.9%)
|
174.59M
est: 166.21M (+5.0%)
|
245.55M
est: 255.11M (-3.7%)
|
291.00M
est: 278.39M (+4.5%)
|
309.21M
est: 345.87M (-10.6%)
|
363.30M
est: 380.77M (-4.6%)
|
313.95M
est: 269.59M (+16.5%)
|
356.99M
est: 385.29M (-7.3%)
|
403.43M
est: 543.67M (-25.8%)
|
443.48M
427.20M – 455.11M
-18.4% YoY
|
461.67M
444.72M – 473.77M
+4.1% YoY
|
450.46M
433.93M – 462.27M
-2.4% YoY
|
513.95M
495.09M – 527.42M
+14.1% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
386.71M
est: 304.66M (+26.9%)
|
394.19M
est: 291.67M (+35.1%)
|
413.68M
est: 316.09M (+30.9%)
|
419.91M
est: 339.85M (+23.6%)
|
434.79M
est: 360.93M (+20.5%)
|
380.84M
est: 393.56M (-3.2%)
|
393.24M
est: 398.02M (-1.2%)
|
439.80M
est: 423.33M (+3.9%)
|
454.65M
est: 444.15M (+2.4%)
|
490.78M
est: 486.09M (+1.0%)
|
538.13M
est: 519.86M (+3.5%)
|
541.01M
530.79M – 548.01M
+4.1% YoY
|
569.03M
547.91M – 584.41M
+5.2% YoY
|
593.87M
577.11M – 605.85M
+4.4% YoY
|
629.00M
611.25M – 641.69M
+5.9% YoY
|
716.48M
696.25M – 730.93M
+13.9% YoY
|
| EPS |
4.86
est: 5.40 (-10.0%)
|
3.35
est: 3.49 (-4.1%)
|
4.74
est: 4.51 (+5.1%)
|
5.46
est: 5.40 (+1.1%)
|
7.73
est: 8.29 (-6.7%)
|
9.27
est: 9.04 (+2.5%)
|
9.92
est: 11.24 (-11.7%)
|
11.69
est: 12.37 (-5.5%)
|
10.14
est: 8.76 (+15.8%)
|
11.60
est: 12.37 (-6.3%)
|
12.96
est: 17.46 (-25.8%)
|
14.24
13.72 – 14.62
-18.4% YoY
|
14.83
14.28 – 15.22
+4.1% YoY
|
14.47
13.94 – 14.85
-2.4% YoY
|
16.51
15.90 – 16.94
+14.1% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joe Colaric | President of Management Board & Chief Executive Officer | 2M | — |
| Ales Rotar | Member of the Management Board and Director of Pharmaceutical R&D & Production | 1M | — |
| Vinko Zupancic | Director of API R&D, Production & Supply Chain and Member of the Management Board | 934.0K | — |
| David Bratoz | Member of the Management Board | 927.0K | male |
| Milena Kastelic | Member of the Mgt. Board, Worker Director & Deputy Dir. of Pharmaceutical Production | 339.0K | female |
| Mateja Vrecer | Director of Quality Management & Employee Representative Deputy President of the Supervisory Board | 48.3K | — |
| Magistrate Toma Sever | Dty Director of Sales, Director of Region Central Europe & Ind Employee Rep Member of Super Board | 46.8K | — |
| Mari Bozic | Employee Representative Supervisory Board Member & Assistant Head of Pharmaceutical Development | 33.1K | — |
| Matej Baselj | Technical Director | — | — |
| Uros Ozbolt | Director of Finance | — | — |
| Borut Leke | Deputy Chief Executive Officer of Legal Affairs & Head of Legal Affairs | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KRK.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
